Hypertension and Cognitive Function

Clinics in Geriatric Medicine

Volumn 25, Issue 2, 2009, Pages 259-288

  Obisesan, Thomas Olabode ^a  

^a HOWARD UNIVERSITY HOSPITAL   (United States)

Author keywords

Aging; Alzheimer's disease; Dementia; Hypertension; Memory; Prevention; Treatment

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LOOP DIURETIC AGENT; LOSARTAN; NITRENDIPINE; NITRIC OXIDE; OXYGEN; PERINDOPRIL; PLACEBO;

ALZHEIMER DISEASE; AUTOREGULATION; BRAIN PERFUSION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; FOLLOW UP; GENE LOCUS; GENETIC VARIABILITY; HUMAN; HYPERTENSION; INCIDENCE; MEMORY; METABOLIC DISORDER; PATHOGENESIS; PHENOTYPE; PROGNOSIS; PROSPECTIVE STUDY; PULSE RATE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; ANTIHYPERTENSIVE AGENTS; COGNITION DISORDERS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYPERTENSION; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67449099097     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cger.2009.03.002     Document Type: Review

References (136)

1. Johnson P. Fiscal implications of population ageing. Philos Trans R Soc Lond B Biol Sci 352 (1997) 1895-1903
2. Serow W.J. Economic and fiscal implications of aging for subnational American governments. J Aging Soc Policy 12 (2001) 47-63
3. Covinsky K.E., Eng C., Lui L.Y., et al. The last 2 years of life: functional trajectories of frail older people. J Am Geriatr Soc 51 (2003) 492-498
4. Hamel E., Nicolakakis N., Aboulkassim T., et al. Oxidative stress and cerebrovascular dysfunction in mouse models of Alzheimer's disease. Exp Physiol 93 (2008) 116-120
5. Breteler M.M., van den Ouweland F.A., Grobbee D.E., et al. A community-based study of dementia: the Rotterdam Elderly Study. Neuroepidemiology 11 Suppl 1 (1992) 23-28
6. Hachinski V., and Munoz D.G. Cerebrovascular pathology in Alzheimer's disease: cause, effect or epiphenomenon?. Ann N Y Acad Sci 826 (1997) 1-6
7. White L., Petrovitch H., Hardman J., et al. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia aging study participants. Ann N Y Acad Sci 977 (2002) 9-23
8. Van Nostrand W.E., Davis-Salinas J., and Saporito-Irwin S.M. Amyloid beta-protein induces the cerebrovascular cellular pathology of Alzheimer's disease and related disorders. Ann N Y Acad Sci 777 (1996) 297-302
9. Tzourio C. Hypertension, cognitive decline, and dementia: an epidemiological perspective. Dialogues Clin Neurosci 9 (2007) 61-70
10. Peila R., White L.R., Masaki K., et al. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke 37 (2006) 1165-1170
11. Kivipelto M., Helkala E.L., Hanninen T., et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 56 (2001) 1683-1689
12. Launer L.J., Ross G.W., Petrovitch H., et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 21 (2000) 49-55
13. Skoog I., Lernfelt B., Landahl S., et al. 15-year longitudinal study of blood pressure and dementia. Lancet 347 (1996) 1141-1145
14. Frishman W.H. Are antihypertensive agents protective against dementia? A review of clinical and preclinical data. Heart Dis 4 (2002) 380-386
15. Manolio T.A., Olson J., and Longstreth W.T. Hypertension and cognitive function: pathophysiologic effects of hypertension on the brain. Curr Hypertens Rep 5 (2003) 255-261
16. Korf E.S., White L.R., Scheltens P., et al. Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia aging study. Hypertension 44 (2004) 29-34
17. Obisesan T.O., Obisesan O.A., Martins S., et al. High blood pressure, hypertension, and high pulse pressure are associated with poorer cognitive function in persons aged 60 and older: the Third National Health and Nutrition Examination Survey. J Am Geriatr Soc 56 (2008) 501-509
18. Forette F., Seux M.L., Staessen J.A., et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352 (1998) 1347-1351
19. Forette F., Seux M.L., Staessen J.A., et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 162 (2002) 2046-2052
20. Tzourio C., Anderson C., Chapman N., et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 163 (2003) 1069-1075
21. Bosch J., Yusuf S., Pogue J., et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 324 (2002) 699-702
22. Peters R., Beckett N., Forette F., et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 7 (2008) 683-689
23. Kahonen-Vare M., Brunni-Hakala S., Lindroos M., et al. Left ventricular hypertrophy and blood pressure as predictors of cognitive decline in old age. Aging Clin Exp Res 16 (2004) 147-152
24. Kuo H.K., Sorond F., Iloputaife I., et al. Effect of blood pressure on cognitive functions in elderly persons. J Gerontol A Biol Sci Med Sci 59 (2004) 1191-1194
25. Waldstein S.R., Brown J.R., Maier K.J., et al. Diagnosis of hypertension and high blood pressure levels negatively affect cognitive function in older adults. Ann Behav Med 29 (2005) 174-180
26. Waldstein S.R., and Katzel L.I. Stress-induced blood pressure reactivity and cognitive function. Neurology 64 (2005) 1746-1749
27. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157 (1997) 2413-2446
28. St Clair D., and Whalley L.J. Hypertension, multi-infarct dementia and Alzheimer's disease. Br J Psychiatry 143 (1983) 274-276
29. Sadowski M., Pankiewicz J., Scholtzova H., et al. Links between the pathology of Alzheimer's disease and vascular dementia. Neurochem Res 29 (2004) 1257-1266
30. Reitz C., Patel B., Tang M.X., et al. Relation between vascular risk factors and neuropsychological test performance among elderly persons with Alzheimer's disease. J Neurol Sci 257 (2007) 194-201
31. Petrovitch H., Ross G.W., Steinhorn S.C., et al. AD lesions and infarcts in demented and non-demented Japanese-American men. Ann Neurol 57 (2005) 98-103
32. Petrovitch H., White L.R., Izmirilian G., et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging study. Neurobiol Aging 21 (2000) 57-62
33. Cacciatore F., Abete P., Ferrara N., et al. The role of blood pressure in cognitive impairment in an elderly population. Osservatorio Geriatrico Campano Group. J Hypertens 15 (1997) 135-142
34. Richards S.S., Emsley C.L., Roberts J., et al. The association between vascular risk factor-mediating medications and cognition and dementia diagnosis in a community-based sample of African-Americans. J Am Geriatr Soc 48 (2000) 1035-1041
35. Hajjar I., Catoe H., Sixta S., et al. Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population. J Gerontol A Biol Sci Med Sci 60 (2005) 67-73
36. Lindsay J., Laurin D., Verreault R., et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian study of health and aging. Am J Epidemiol 156 (2002) 445-453
37. Morris M.S., Jacques P.F., Rosenberg I.H., et al. Hyperhomocysteinemia associated with poor recall in the third National Health and Nutrition Examination Survey. Am J Clin Nutr 73 (2001) 927-933
38. Duron E., and Hanon O. Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag 4 (2008) 363-381
39. Bellew K.M., Pigeon J.G., Stang P.E., et al. Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 18 (2004) 208-213
40. Hanon O., Haulon S., Lenoir H., et al. Relationship between arterial stiffness and cognitive function in elderly subjects with complaints of memory loss. Stroke 36 (2005) 2193-2197
41. Verghese J., Lipton R.B., Hall C.B., et al. Low blood pressure and the risk of dementia in very old individuals. Neurology 61 (2003) 1667-1672
42. Sparks D.L., Scheff S.W., Liu H., et al. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci 131 (1995) 162-169
43. Guo Z., Viitanen M., Winblad B., et al. Low blood pressure and incidence of dementia in a very old sample: dependent on initial cognition. J Am Geriatr Soc 47 (1999) 723-726
44. Tzourio C., Dufouil C., Ducimetiere P., et al. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging. Neurology 53 (1999) 1948-1952
45. Murray M.D., Lane K.A., Gao S., et al. Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African Americans. Arch Intern Med 162 (2002) 2090-2096
46. Yasar S., Corrada M., Brookmeyer R., et al. Calcium channel blockers and risk of AD: the Baltimore longitudinal study of aging. Neurobiol Aging 26 (2005) 157-163
47. Khachaturian A.S., Zandi P.P., Lyketsos C.G., et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol 63 (2006) 686-692
48. Salas M., In't Veld B.A., van der Linden P.D., et al. Impaired cognitive function and compliance with antihypertensive drugs in elderly: the Rotterdam Study. Clin Pharmacol Ther 70 (2001) 561-566
49. Hanon O., Pequignot R., Seux M.L., et al. Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints. J Hypertens 24 (2006) 2101-2107
50. Starr J.M., Whalley L.J., and Deary I.J. The effects of antihypertensive treatment on cognitive function: results from the HOPE study. J Am Geriatr Soc 44 (1996) 411-415
51. Feigin V., Ratnasabapathy Y., and Anderson C. Does blood pressure lowering treatment prevent dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease?. J Neurol Sci 229-230 (2005) 151-155
52. Birkenhager W.H., and Staessen J.A. Progress in cardiovascular diseases: cognitive function in essential hypertension. Prog Cardiovasc Dis 49 (2006) 1-10
53. Prince M.J., Bird A.S., Blizard R.A., et al. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ 312 (1996) 801-805
54. Lithell H., Hansson L., Skoog I., et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21 (2003) 875-886
55. McGuinness B., Todd S., Passmore P., et al. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst Rev 2 (2006) CD004034
56. Gard P.R. Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Expert Opin Ther Targets 8 (2004) 7-14
57. Heckbert S.R., Longstreth Jr. W.T., Psaty B.M., et al. The association of antihypertensive agents with MRI white matter findings and with modified mini-mental state examination in older adults. J Am Geriatr Soc 45 (1997) 1423-1433
58. Maxwell C.J., Hogan D.B., and Ebly E.M. Calcium-channel blockers and cognitive function in elderly people: results from the Canadian study of health and aging. CMAJ 161 (1999) 501-506
59. Morris M.C., Scherr P.A., Hebert L.E., et al. Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol 58 (2001) 1640-1646
60. Qiu C., von Strauss E., Fastbom J., et al. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol 60 (2003) 223-228
61. Qiu C., von Strauss E., Winblad B., et al. Decline in blood pressure over time and risk of dementia: a longitudinal study from the Kungsholmen project. Stroke 35 (2004) 1810-1815
62. Ruitenberg A., Skoog I., Ott A., et al. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 12 (2001) 33-39
63. Lee A.Y., Jeong S.H., Choi B.H., et al. Pulse pressure correlates with leukoaraiosis in Alzheimer disease. Arch Gerontol Geriatr 42 (2006) 157-166
64. Waldstein S.R., Giggey P.P., Thayer J.F., et al. Nonlinear relations of blood pressure to cognitive function: the Baltimore Longitudinal Study of Aging. Hypertension 45 (2005) 374-379
65. Qiu C., Winblad B., Viitanen M., et al. Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: a community-based, longitudinal study. Stroke 34 (2003) 594-599
66. Morris M.C., Scherr P.A., Hebert L.E., et al. Association between blood pressure and cognitive function in a biracial community population of older persons. Neuroepidemiology 21 (2002) 123-130
67. Perlmutter L.S., Barron E., Saperia D., et al. Association between vascular basement membrane components and the lesions of Alzheimer's disease. J Neurosci Res 30 (1991) 673-681
68. Hardy J.A., Mann D.M., Wester P., et al. An integrative hypothesis concerning the pathogenesis and progression of Alzheimer's disease. Neurobiol Aging 7 (1986) 489-502
69. Lukiw W.J., and Bazan N.G. Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex. J Neurosci Res 50 (1997) 937-945
70. Perkins D.J., and Kniss D.A. Tumor necrosis factor-alpha promotes sustained cyclooxygenase-2 expression: attenuation by dexamethasone and NSAIDs. Prostaglandins 54 (1997) 727-743
71. Modzelewski R., de la Rue T., Janvresse E., et al. Development and validation of the random walk algorithm: application to the classification of diffuse heterogeneity in brain SPECT perfusion images. J Comput Assist Tomogr 32 (2008) 651-659
72. Waragai M., Mizumura S., Yamada T., et al. Differentiation of early-stage Alzheimer's disease from other types of dementia using brain perfusion single photon emission computed tomography with easy Z-score imaging system analysis. Dement Geriatr Cogn Disord 26 (2008) 547-555
73. Kobayashi S., Tateno M., Utsumi K., et al. Quantitative analysis of brain perfusion SPECT in Alzheimer's disease using a fully automated regional cerebral blood flow quantification software, 3DSRT. J Neurol Sci 264 (2008) 27-33
74. Tsolaki M., Sakka V., Gerasimou G., et al. Correlation of rCBF (SPECT), CSF tau, and cognitive function in patients with dementia of the Alzheimer's type, other types of dementia, and control subjects. Am J Alzheimers Dis Other Demen 16 (2001) 21-31
75. Ueda H., Kitabayashi Y., Narumoto J., et al. Relationship between clock drawing test performance and regional cerebral blood flow in Alzheimer's disease: a single photon emission computed tomography study. Psychiatry Clin Neurosci 56 1 (2002) 25-29
76. Jagust W.J., Eberling J.L., Reed B.R., et al. Clinical studies of cerebral blood flow in Alzheimer's disease. Ann N Y Acad Sci 826 (1997) 254-262
77. Ushijima Y., Okuyama C., Mori S., et al. Relationship between cognitive function and regional cerebral blood flow in Alzheimer's disease. Nucl Med Commun 23 (2002) 779-784
78. Nagahama Y., Nabatame H., Okina T., et al. Cerebral correlates of the progression rate of the cognitive decline in probable Alzheimer's disease. Eur Neurol 50 (2003) 1-9
79. Bots M.L., Witteman J.C., Hofman A., et al. Low diastolic blood pressure and atherosclerosis in elderly subjects. The Rotterdam study. Arch Intern Med 156 (1996) 843-848
80. Liao D., Arnett D.K., Tyroler H.A., et al. Arterial stiffness and the development of hypertension. The ARIC study. Hypertension 34 (1999) 201-206
81. Chambless L.E., Folsom A.R., Davis V., et al. Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol 155 (2002) 38-47
82. Farkas E., and Luiten P.G. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 64 (2001) 575-611
83. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 5 (2004) 347-360
84. Iadecola C., Zhang F., Niwa K., et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci 2 (1999) 157-161
85. Niwa K., Porter V.A., Kazama K., et al. A beta-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol 281 (2001) H2417-H2424
86. Crawford F., Suo Z., Fang C., et al. Characteristics of the in vitro vasoactivity of beta-amyloid peptides. Exp Neurol 150 (1998) 159-168
87. Zlokovic B.V., Deane R., Sallstrom J., et al. Neurovascular pathways and Alzheimer amyloid beta-peptide. Brain Pathol 15 (2005) 78-83
88. Attwell D., and Iadecola C. The neural basis of functional brain imaging signals. Trends Neurosci 25 (2002) 621-625
89. Ide K., and Secher N.H. Cerebral blood flow and metabolism during exercise. Prog Neurobiol 61 (2000) 397-414
90. Wolf R.L., Alsop D.C., Levy-Reis I., et al. Detection of mesial temporal lobe hypoperfusion in patients with temporal lobe epilepsy by use of arterial spin labeled perfusion MR imaging. AJNR Am J Neuroradiol 22 (2001) 1334-1341
91. Heistad D.D. Summary of symposium on cerebral blood flow: effect of nerves and neurotransmitters. Cardiovascular Center, University of Iowa, Iowa City, Iowa, June 16-18, 1981. J Cereb Blood Flow Metab 1 (1981) 447-450
92. Baumbach G.L., and Heistad D.D. Regional, segmental, and temporal heterogeneity of cerebral vascular autoregulation. Ann Biomed Eng 13 (1985) 303-310
93. Daley M.L., Pourcyrous M., Timmons S.D., et al. Assessment of cerebrovascular autoregulation: changes of highest modal frequency of cerebrovascular pressure transmission with cerebral perfusion pressure. Stroke 35 (2004) 1952-1956
94. de la Torre J.C. Critical threshold cerebral hypoperfusion causes Alzheimer's disease?. Acta Neuropathol 98 (1999) 1-8
95. de la Torre J.C. Impaired cerebromicrovascular perfusion. Summary of evidence in support of its causality in Alzheimer's disease. Ann N Y Acad Sci 924 (2000) 136-152
96. de la Torre J.C. Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol Aging 21 (2000) 331-342
97. de la Torre J.C. Cerebral hypoperfusion, capillary degeneration, and development of Alzheimer disease. Alzheimer Dis Assoc Disord 14 Suppl 1 (2000) S72-S81
98. de la Torre J.C. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33 (2002) 1152-1162
99. Prunell G.F., Mathiesen T., and Svendgaard N.A. Experimental subarachnoid hemorrhage: cerebral blood flow and brain metabolism during the acute phase in three different models in the rat. Neurosurgery 54 (2004) 426-436 [discussion: 36-7]
100. Warkentin S., Ohlsson M., Wollmer P., et al. Regional cerebral blood flow in Alzheimer's disease: classification and analysis of heterogeneity. Dement Geriatr Cogn Disord 17 (2004) 207-214
101. Johnson K.A., Jones K., Holman B.L., et al. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 50 (1998) 1563-1571
102. Matsuda H. Cerebral blood flow and metabolic abnormalities in Alzheimer's disease. Ann Nucl Med 15 (2001) 85-92
103. Reckelhoff J.F., and Romero J.C. Role of oxidative stress in angiotensin-induced hypertension. Am J Physiol Regul Integr Comp Physiol 284 (2003) R893-R912
104. Amouyel P., Richard F., Berr C., et al. The renin angiotensin system and Alzheimer's disease. Ann N Y Acad Sci 903 (2000) 437-441
105. McKinley M.J., Albiston A.L., Allen A.M., et al. The brain renin-angiotensin system: location and physiological roles. Int J Biochem Cell Biol 35 (2003) 901-918
106. Gard P.R. The role of angiotensin II in cognition and behaviour. Eur J Pharmacol 438 (2002) 1-14
107. Sharma P. Meta-analysis of the ACE gene in ischaemic stroke. J Neurol Neurosurg Psychiatr 64 (1998) 227-230
108. Phillips M.I., and de Oliveira E.M. Brain renin angiotensin in disease. J Mol Med 86 (2008) 715-722
109. Markus H.S., Barley J., Lunt R., et al. Angiotensin-converting enzyme gene deletion polymorphism. A new risk factor for lacunar stroke but not carotid atheroma. Stroke 26 (1995) 1329-1333
110. von Bohlen und Halbach O., and Albrecht D. The CNS renin-angiotensin system. Cell Tissue Res 326 (2006) 599-616
111. Raghavendra V., Chopra K., and Kulkarni S.K. Comparative studies on the memory-enhancing actions of captopril and losartan in mice using inhibitory shock avoidance paradigm. Neuropeptides 35 (2001) 65-69
112. Bonini J.S., Bevilaqua L.R., Zinn C.G., et al. Angiotensin II disrupts inhibitory avoidance memory retrieval. Horm Behav 50 (2006) 308-313
113. de Souza F.A., Sanchis-Segura C., Fukada S.Y., et al. Intracerebroventricular effects of angiotensin II on a step-through passive avoidance task in rats. Neurobiol Learn Mem 81 (2004) 100-103
114. Hu J., Igarashi A., Kamata M., et al. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 276 (2001) 47863-47868
115. Denny J.B., Polan-Curtain J., Wayner M.J., et al. Angiotensin II blocks hippocampal long-term potentiation. Brain Res 567 (1991) 321-324
116. Baranowska D., Braszko J.J., and Wisniewski K. Effect of angiotensin II and vasopressin on acquisition and extinction of conditioned avoidance in rats. Psychopharmacology (Berl) 81 (1983) 247-251
117. Selley M.L. Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiol Aging 24 (2003) 903-907
118. McCarron R.M., Chen Y., Tomori T., et al. Endothelial-mediated regulation of cerebral microcirculation. J Physiol Pharmacol 57 Suppl 11 (2006) 133-144
119. Maxwell A.J. Mechanisms of dysfunction of the nitric oxide pathway in vascular diseases. Nitric Oxide 6 (2002) 101-124
120. Cooke J.P., and Dzau V.J. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 48 (1997) 489-509
121. Chen Z.Y., Su Y.L., Lau C.W., et al. Endothelium-dependent contraction and direct relaxation induced by baicalein in rat mesenteric artery. Eur J Pharmacol 374 (1999) 41-47
122. Rodrigo J., Fernandez A.P., Alonso D., et al. Nitric oxide in the rat cerebellum after hypoxia/ischemia. Cerebellum 3 (2004) 194-203
123. Fernandez-Vizarra P., Fernandez A.P., Castro-Blanco S., et al. Expression of nitric oxide system in clinically evaluated cases of Alzheimer's disease. Neurobiol Dis 15 (2004) 287-305
124. Rodrigo J., Fernandez-Vizarra P., Castro-Blanco S., et al. Nitric oxide in the cerebral cortex of amyloid-precursor protein (SW) Tg2576 transgenic mice. Neuroscience 128 (2004) 73-89
125. Lee T.J. Nitric oxide and the cerebral vascular function. J Biomed Sci 7 (2000) 16-26
126. Nakajima K., Uchida S., Suzuki A., et al. The effect of walking on regional blood flow and acetylcholine in the hippocampus in conscious rats. Auton Neurosci 103 (2003) 83-92
127. Moro V., Kacem K., Springhetti V., et al. Microvessels isolated from brain: localization of muscarinic sites by radioligand binding and immunofluorescent techniques. J Cereb Blood Flow Metab 15 (1995) 1082-1092
128. Hamel E. Cholinergic modulation of the cortical microvascular bed. Prog Brain Res 145 (2004) 171-178
129. Tong X.K., and Hamel E. Regional cholinergic denervation of cortical microvessels and nitric oxide synthase-containing neurons in Alzheimer's disease. Neuroscience 92 (1999) 163-175
130. Martel C.L., Mackic J.B., Matsubara E., et al. Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta. J Neurochem 69 (1997) 1995-2004
131. Rigat B., Hubert C., Alhenc-Gelas F., et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86 (1990) 1343-1346
132. Alvarez R., Alvarez V., Lahoz C.H., et al. Angiotensin converting enzyme and endothelial nitric oxide synthase DNA polymorphisms and late onset Alzheimer's disease. J Neurol Neurosurg Psychiatr 67 (1999) 733-736
133. Monastero R., Caldarella R., Mannino M., et al. Lack of association between angiotensin converting enzyme polymorphism and sporadic Alzheimer's disease. Neurosci Lett 335 (2002) 147-149
134. Lendon C.L., Thaker U., Harris J.M., et al. The angiotensin 1-converting enzyme insertion (I)/deletion (D) polymorphism does not influence the extent of amyloid or tau pathology in patients with sporadic Alzheimer's disease. Neurosci Lett 328 (2002) 314-318
135. Bartres-Faz D., Junque C., Clemente I.C., et al. Angiotensin I converting enzyme polymorphism in humans with age-associated memory impairment: relationship with cognitive performance. Neurosci Lett 290 (2000) 177-180
136. Richard F., Berr C., Amant C., et al. Effect of the angiotensin I-converting enzyme I/D polymorphism on cognitive decline. The EVA Study Group. Neurobiol Aging 21 (2000) 75-80